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ABSTRACT
Introduction: Maintenance of drug efficacy
and safety over the long term is important to
investigate for progressive conditions like type 2
diabetes mellitus (T2DM). This study aimed to
evaluate whether efficacy of dapagliflozin added
to glimepiride observed at 24 weeks was
maintained at 48 weeks, and to provide further
safety and tolerability data in patients with
T2DM.
Methods: This 24-week randomized,
double-blind, parallel-group, placebo-controlled
trial with a 24-week double-blind extension
period enrolled adults whose T2DM was
inadequately controlled [glycated hemoglobin
(HbA1c) 7.0–10.0%] on sulfonylurea
monotherapy. Patients were randomized to
placebo (n = 146) or dapagliflozin 2.5 mg
(n = 154), 5 mg (n = 145), or 10 mg (n = 151) per
day added to open-label glimepiride 4 mg/day.
Results: In total, 519 patients (87.1%)
completed the study. At 48 weeks, HbA1c
adjusted mean changes from baseline for the
placebo versus dapagliflozin 2.5/5/10-mg
groups were -0.04% versus -0.41%, -0.56%
and -0.73%, respectively. There were no
meaningful differences in HbA1c changes from
baseline from 24 to 48 weeks, indicating that
glycemic efficacy was maintained.
Improvements in fasting plasma glucose and
post-challenge plasma glucose were also
observed with dapagliflozin over 48 weeks.
Dapagliflozin 2.5/5/10 mg produced sustained
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reductions in weight (-1.36/-1.54/-2.41 kg)
versus placebo (-0.77 kg). Adjusted mean
reductions from baseline in systolic blood
pressure were also greater than placebo for all
dapagliflozin doses. In the placebo versus
dapagliflozin groups, serious adverse events
were 8.9% versus 8.6–11.0%, hypoglycemic
events were 6.8% versus 9.7–11.3%, and events
suggestive of genital infection were 1.4% versus
5.2–8.6%.
Conclusion: Dapagliflozin added to glimepiride
improved glycemic control and body weight,
with short-term findings maintained during the
study’s extension period. Therapy was generally
well tolerated over 48 weeks; hypoglycemic
events and events suggestive of genital




co-transporter 2 (SGLT2) inhibitor;
Sulfonylureas; Type 2 diabetes mellitus
INTRODUCTION
Sulfonylureas are commonly used in the
medical management of type 2 diabetes
mellitus (T2DM) after diet and exercise have
failed; however, their long-term effectiveness is
poor [1, 2]. Loss of efficacy with
glucose-lowering agents over time, particularly
with sulfonylureas, is a consequence of
progressive worsening of diabetes,
characterized by loss of b-cell function [3].
Dapagliflozin, a competitive, reversible, and
highly selective inhibitor of sodium–glucose
co-transporter 2 (SGLT2), increases urinary
glucose excretion and reduces hyperglycemia
independently of insulin secretion or action
[4–7]. Thus, its efficacy is expected to be
complementary to that of agents with
insulin-dependent mechanisms of action. We
previously published results from the first
24 weeks of a double-blind study in patients
with T2DM inadequately controlled on
sulfonylurea monotherapy, which showed that
dapagliflozin added to glimepiride significantly
reduced glycated hemoglobin (HbA1c), fasting
plasma glucose (FPG), post-challenge plasma
glucose, and weight compared with placebo
added to glimepiride [8]. When considering
newer, insulin-independent treatments such as
the SGLT2 inhibitor, dapagliflozin,
maintenance of efficacy achieved in the
short-term over a longer period of time is
important to establish, particularly for
chronic, progressive conditions such as T2DM
where some conventional, insulin-dependent
therapies are associated with loss of efficacy
over time [2, 9].
The objectives of the present analysis were to
evaluate whether efficacy of dapagliflozin at
24 weeks was maintained after 48 weeks of
treatment and to provide further safety and
tolerability data with dapagliflozin.
MATERIALS AND METHODS
Patients
Patients aged C18 years with inadequately
controlled T2DM (defined as HbA1c C7.0% and
B10.0%), and who were receiving a stable dose
of sulfonylurea monotherapy at a level of at
least half the maximum recommended dose for
at least 8 weeks prior to enrollment, were
eligible for inclusion. In view of the
observation that the glucose-lowering effects
of sulfonylureas start to reach a plateau at
half-maximal doses, and higher doses are not
recommended because of excessive risk of
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hypoglycemia [2], the patients included in this
study were highly likely to have been exposed
to a maximally effective dose of glimepiride. In
addition, patients had to have an FPG
B15 mmol/L and fasting C-peptide
C0.33 nmol/L.
Study Design
This was a 48-week randomized, double-blind,
parallel-group, placebo-controlled, phase III
trial that included a 24-week double-blind,
short-term treatment period with a 24-week
site- and subject-blinded, long-term extension
period conducted from April 2008 to November
2009 at 84 sites in Europe and Asia. The study
complied with the Declaration of Helsinki and
the International Conference on
Harmonisation/Good Clinical Practice
Guidelines (July 1996). It was approved by
institutional review boards and independent
ethics committees for participating centers and
is registered with ClinicalTrials.gov
(NCT00680745). All participants provided
informed consent. Full details of the study
methods of the 24-week short-term,
double-blind treatment period have been
previously published [8]. A brief summary of
study methods is as follows.
Study Treatments and Interventions
Eligible patients either continued with, or were
switched to, open-label glimepiride 4 mg/day
during the 8-week lead-in period. During a
1-week qualification period, all
inclusion/exclusion criteria were reviewed in
those patients switched to glimepiride
4 mg/day, as previously described [8]. Those
patients still meeting the study eligibility
criteria were randomized to receive
double-blind dapagliflozin 2.5, 5, or 10 mg, or
placebo, taken orally once daily before the first
meal of the day, while continuing open-label
glimepiride 4 mg/day. Open-label glimepiride
could be downtitrated to 2 mg or discontinued
to mitigate recurrent hypoglycemic events at
the discretion of the investigator. However, no
uptitration was allowed.
Patients with inadequate glycemic control
during the treatment period remained in the
trial but received open-label rescue therapy with
metformin or pioglitazone, or rosiglitazone (if
pioglitazone was unavailable). The following
were the progressively more stringent glycemic
levels for defining inadequate glycemic control
and eligibility for rescue therapy: a central
laboratory FPG (confirmed on a second
measurement within 3–5 days) [15 mmol/L
(weeks 4–8); an FPG [13.2 mmol/L (weeks
8–12); or an FPG [11.1 mmol/L (weeks 12–24).
Patients with an HbA1c level [8.0% for a
continuous 12-week period, despite maximum
tolerated dose of rescue therapy, discontinued
the trial. From 24 to 48 weeks, the criterion for
rescue was a central laboratory HbA1c value
C8.0%.
All patients received dietary and lifestyle
counseling. In addition, patients with a body
mass index of C27 kg/m2 received advice
concerning reducing caloric intake and exercise.
Details of the randomization schedule and
methods for maintaining allocation
concealment have been previously published [8].
Outcome Measures
The primary efficacy assessment was at
24 weeks. Specified exploratory efficacy
assessments included: change in HbA1c
percentage from baseline to week 48;
proportions of patients achieving a therapeutic
glycemic response (defined as HbA1c\7.0% and
B6.5% at week 48); change in total body weight
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from baseline to week 48; change from baseline
to week 48 in 2-hour post-challenge plasma
glucose rise in response to an oral glucose
tolerance test (OGTT); change in FPG from
baseline to week 48; Diabetes Treatment
Satisfaction Questionnaire (DTSQ) status at
week 48; proportions of patients receiving
rescue therapy for failing to reach prespecified
glycemic targets or discontinuing for lack of
efficacy; seated systolic and diastolic blood
pressure (SBP and DBP, respectively); and lipid
parameters. Details of OGTT administration
have been published previously [8].
Safety and tolerability were evaluated by
assessment of adverse events (AEs), laboratory
values, electrocardiogram, pulse rate, blood
pressure, hypoglycemic events, and calculated
creatinine clearance as previously published [8].
A prespecified list of Medical Dictionary for
Regulatory Activities (MedDRA) version 13.0
preferred terms identified signs, symptoms, and
other reports suggestive of urinary tract
infection (UTI) and genital infection in the
database. This list included terms for
nonspecific signs and symptoms suggestive of
genital infection (e.g., genital pruritus,
vulvovaginal pruritus) as well as terms for
clinical infection (e.g., vaginal infection), but
did not include terms for sexually transmitted
diseases. Patients reported these events both
spontaneously and in response to proactive
questioning by the investigators during study
visits.
Statistical Analysis
The continuous efficacy analyses over 48 weeks
were based on longitudinal repeated measures
analyses using ‘‘direct likelihood’’ without
imputation of missing data. The SAS
procedure PROC MIXED (SAS Institute Inc,
Cary, NC, USA) was used, and model terms
included the fixed categorical effects of
treatment, week and treatment-by-week
interaction, and the continuous fixed
covariates of baseline measurement and
baseline measurement-by-week interaction.
No statistical hypothesis testing was
performed for the combined short-term plus
extension periods from baseline to week 48,
but point estimates and 95% confidence
intervals (CIs) were provided. Categorical
efficacy variables were analyzed using logistic
regression methodology from Zhang et al. [10]
with adjustment for baseline value. Patients
with missing data were included in these
analyses and considered non-responders. The
Kaplan–Meier method was used to analyze
time to onset of rescue therapy for failing to
achieve prespecified glycemic targets or patient
discontinuation due to poor glycemic control.
Efficacy analyses exclude data after rescue,
unless otherwise stated. Safety analyses
include data after rescue.
Definitions of the full analysis set and safety
analysis set and sample size calculations were as
previously published [8]. Safety data were




Detailed demographic and clinical
characteristics at baseline were previously
reported and balanced across the treatment
groups [8]. Key baseline characteristics are
summarized in Table 1. The majority of
randomized patients completed the short-term
and the extension periods [519 patients
(87.1%)], with the most common reasons for
discontinuation being withdrawal of consent
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and AEs [Supplementary Figure S1 in the
electronic supplementary material (ESM)].
Efficacy Variables
Adjusted mean changes in HbA1c from baseline
at 48 weeks after dapagliflozin 2.5, 5, and 10 mg
were added to glimepiride were -0.41 (95% CI
-0.56, -0.26), -0.56 (95% CI -0.71, -0.41),
and -0.73 percentage points (95% CI -0.87,
-0.59), respectively, versus -0.04 percentage
points (95% CI -0.21, 0.14) in the placebo plus
glimepiride group (excluding data after rescue
therapy; Fig. 1a). Differences between the
dapagliflozin and placebo groups were
statistically significant at 24 weeks [8] and
were maintained at 48 weeks with placebo-
corrected reductions of -0.37 percentage
points (95% CI -0.60, -0.14) in the
dapagliflozin 2.5-mg group, -0.53 percentage
points (95% CI -0.75, -0.30) in the 5-mg
group, and -0.70 percentage points (95% CI
-0.92, -0.47) in the 10-mg group. In analyses
that included data after rescue therapy, HbA1c
changes with dapagliflozin added to glimepiride
were similar (Supplementary Figure S2 in the
ESM). Comparisons of 24-week versus 48-week
HbA1c change from baseline values (excluding
data after rescue therapy) revealed no
substantive differences in placebo-corrected
reductions between these time points
(Supplementary Table S1 in the ESM).
The proportion of patients achieving an
HbA1c \7.0% or \6.5% was significantly
increased with dapagliflozin 5 and 10 mg
versus placebo at 24 weeks [8]. This was
maintained at week 48, with the proportions
of patients achieving an HbA1c\7.0% higher in




Dapagliﬂozin 2.5 mg 1
glimepiride (N5 154)
Dapagliﬂozin 5 mg 1
glimepiride (N5 142)
Dapagliﬂozin 10 mg 1
glimepiride (N5 151)
Age (years) 60.3 ± 10.2 59.9 ± 10.1 60.2 ± 9.7 58.9 ± 8.3
Type 2 diabetes
duration (years)
7.4 ± 5.7 7.7 ± 6.0 7.4 ± 5.7 7.2 ± 5.5
Male (%) 49.0 50.0 50.0 43.7
BMI (kg/m2) 29.7 ± 4.6 30.0 ± 5.1 29.8 ± 5.2 29.8 ± 5.6
HbA1c (%) 8.15 ± 0.74 8.11 ± 0.75 8.12 ± 0.78 8.07 ± 0.79
FPG (mmol/L) 9.58 ± 2.07 9.56 ± 2.13 9.68 ± 2.12 9.55 ± 2.04
Prior history of
CVDa (%)
37.9 36.4 38.7 30.5




28.4 ± 7.1 27.8 ± 6.0 27.4 ± 6.0 27.6 ± 6.5
All data are mean ± standard deviation, unless otherwise speciﬁed
BMI body mass index, CVD cardiovascular disease, DTSQ Diabetes Treatment Satisfaction Questionnaire, FPG fasting
plasma glucose, HbA1c glycated hemoglobin
a At least one event (excluding patients with a history of hypertension only)
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the dapagliflozin 2.5-, 5-, and 10-mg groups
(15.6%, 28.2%, and 30.5%, respectively) than in
the placebo group (10.3%). Corresponding
values for proportions of patients achieving an
HbA1c \6.5% at week 48 were 9.7%, 14.8%,
16.6%, and 2.8%, respectively.
Dapagliflozin also produced sustained
reductions in FPG of up to 1.60 mmol/L at
48 weeks in the 10-mg group (Fig. 1b). Adjusted
mean changes in FPG from baseline at 48 weeks
after dapagliflozin 2.5, 5, and 10 mg were added
to glimepiride were -0.93 (95% CI -1.26,
-0.59), -0.92 (95% CI -1.24, -0.59), and
-1.60 mmol/L (95% CI -1.90, -1.29),
respectively, versus 0.14 mmol/L (95% CI
-0.25, 0.54) in the placebo plus glimepiride
group (excluding data after rescue therapy).
Differences between the dapagliflozin 5- and
10-mg groups and the placebo group were
statistically significant at 24 weeks [8], and
these differences were maintained at 48 weeks
with placebo-corrected reductions of
-1.06 mmol/L (95% CI -1.57, -0.54) and
-1.74 mmol/L (95% CI -2.24, -1.24),
respectively.
The 2-h post-challenge plasma glucose rise in
response to an OGTT was significantly reduced
from baseline at 24 weeks in the dapagliflozin
5- and 10-mg groups [8], and these differences
were maintained at 48 weeks with
placebo-corrected reductions in adjusted mean
change from baseline of -1.38 mmol/L (95% CI
-2.49, -0.27) and -1.20 mmol/L (95% CI
-2.26, -0.14), respectively.
Dapagliflozin produced sustained reductions
in body weight of up to 2.41 kg at 48 weeks in
the 10-mg group (Fig. 1c). Adjusted mean
changes in body weight from baseline at
48 weeks after dapagliflozin 2.5, 5, and 10 mg
were added to glimepiride were -1.36 (95% CI
-1.94, -0.79), -1.54 (95% CI -2.11, -0.96),
and -2.41 kg (95% CI -2.95, -1.87),
respectively, versus -0.77 kg (95% CI -1.43,
-0.12) in the placebo plus glimepiride group
(excluding data after rescue therapy). The
differences between the dapagliflozin 5- and
10-mg groups and the placebo group were
statistically significant at 24 weeks [8]; and the
difference in the dapagliflozin 10-mg group was
maintained at 48 weeks with a
placebo-corrected reduction of -1.64 kg (95%
CI -2.48, -0.79).
Overall, fewer patients in the dapagliflozin
2.5-, 5-, and 10-mg groups discontinued or
received rescue medication due to poor
glycemic control over 48 weeks (32.5%, 29.6%,
and 17.9%, respectively) compared with the
placebo group (53.1%). The probability of
discontinuation or rescue was lower in the
dapagliflozin groups compared with the
placebo group over the entire study period
(Fig. 2). Only 7 patients were discontinued due
to lack of efficacy: 3 in the placebo group
(2.1%), 2 in the dapagliflozin 5-mg group
(1.4%), and 1 each in the dapagliflozin 2.5-
and 10-mg groups (0.6% and 0.7%,
respectively).
For seated SBP, adjusted mean reductions
from baseline at week 48 were greater than
placebo for all dapagliflozin doses (-4.33 to
-6.02 mmHg). For seated DBP, only the
dapagliflozin 10-mg dose showed a meaningful
reduction (-2.94 mmHg) compared with
placebo at week 48 (Supplementary Figure S3
Fig. 1 Change in a HbA1c (%), b FPG, and c body weight
with treatment over 48 weeks (full analysis set) excluding
data after rescue therapy. *Data are adjusted mean changes
from baseline ± 95% conﬁdence interval derived from a
repeated-measures mixed model. N is the number of
patients in the full analysis set, and n is the number of
patients in the full analysis set with non-missing baseline
and week (t) values. Treatment group symbols are shifted
horizontally to prevent error bar overlapping. DAPA
dapagliﬂozin, CI Conﬁdence interval, GLI glimepiride,
HbA1c glycated hemoglobin, PLA placebo
b
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in the ESM). No meaningful changes in heart
rate were observed in any treatment group
(mean change from baseline in seated heart
rate was 0.6, -0.3, 0.2, and 1.6 beats per minute
in the dapagliflozin 2.5, 5, 10-mg groups and
placebo group, respectively).
At week 48, small percentage increases in
high-density lipoprotein cholesterol and free
fatty acids from baseline were seen in the
dapagliflozin treatment groups compared with
placebo, which were slightly more pronounced
at week 48 than at week 24. For low-density
lipoprotein cholesterol, there were no relevant
changes from baseline to week 48; mean
percent changes were -0.6% (95% CI -6.7,
5.6) for placebo and 7.8% (95% CI 1.0, 14.6),
5.7% (95% CI -1.8, 13.3), and 3.9% (95% CI
-1.1, 8.9) for dapagliflozin 2.5-, 5-, and 10-mg
groups, respectively. Similarly, for total
cholesterol and triglycerides, no relevant
changes from baseline to week 48 or from
week 24 to week 48 were noted in any
treatment group (Supplementary Table S2 in
the ESM). Fasting C-peptide at baseline was
above the normal reference range (0.17–0.83
nmol/L) across all groups (Supplementary Table
S2); levels were reduced with dapagliflozin at
week 24 and to a greater extent at week 48.
Fasting C-peptide at week 48 was reduced by
-0.09 (95% CI -0.15, -0.03), -0.10 (95% CI
Fig. 2 Probability of rescue therapy for failing to achieve
prespeciﬁed glycemic targets or of discontinuation because
of poor glycemic control over time. Symbols represent
censored observations. Progressively more stringent
glycemic levels for deﬁning inadequate glycemic control
and hence eligibility for rescue therapy were a Central
laboratory FPG (conﬁrmed on a second measurement
within 3–5 days)[15 mmol/L during weeks 4–8; b an FPG
[13.2 mmol/L during weeks 8–12; c an FPG [11.1
mmol/L during weeks 12–24; and d central laboratory
HbA1c C8.0% during weeks 24–48. DAPA dapagliﬂozin,
FPG fasting plasma glucose, GLI glimepiride, PLA placebo
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-0.20, 0.01), and -0.07 (95% CI -0.14, -0.01)
nmol/L in the dapagliflozin 2.5-, 5-, and 10-mg
groups, respectively, but to a lesser extent in the
placebo group [-0.01 (95% CI -0.14, 0.12)
nmol/L].
Patients’ overall mean DTSQ scores
improved slightly from baseline at week 48,
although values were similar in the
dapagliflozin 2.5-, 5-, and 10-mg groups versus
placebo; 3.5 (95% CI 2.3, 4.6), 4.6 (95% CI 3.2,
5.9), and 4.4 (95% CI 3.1, 5.8), respectively,
versus 2.2 (95% CI 0.5, 3.9).
Safety and Tolerability
AEs and AEs leading to study discontinuation
were balanced across the treatment groups
(Table 2). The frequencies of serious AEs and
AEs reported as drug-related were higher in the
dapagliflozin groups compared with the placebo
group (Table 2).
Serious AEs led to discontinuation of study
medication in eight patients [\2.2% of patients
in each treatment group (Table 2)]: three in the
placebo group (syncope, pulmonary edema, and
multiple stenosis of the coronary arteries), three
in the dapagliflozin 2.5-mg group (neutropenic
fever, chronic lymphatic leukemia, and
gastroduodenitis), one in the dapagliflozin
5-mg group (decompensation of diabetes
mellitus), and one in the dapagliflozin 10-mg
group (stroke). Three deaths were reported,
which were assessed as not related to study
treatment. These included two deaths [1 in the
dapagliflozin 2.5-mg group (cardiopulmonary
arrest) and 1 in the 10-mg group (pulmonary
embolism after ischemic stroke in a patient with
a history of aortic valve replacement)] that
occurred during the short-term period and
have been previously described [8]. During the
extension period, a 66-year-old male patient in
the dapagliflozin 2.5-mg group died of an acute
myocardial infarction.
Hypoglycemic events were reported more
frequently in the dapagliflozin groups
(9.7–11.3%) than in the placebo group (6.8%).
However, no patients were discontinued due to
hypoglycemia (Table 2), and most patients
experienced their first event during the first
24 weeks of treatment (Supplementary Figure S4
in the ESM; excluding data after rescue, but
potential downtitration/discontinuation of
glimepiride should be taken into account
when interpreting these results). There was
only one major episode of hypoglycemia
reported (dapagliflozin 2.5-mg group).
Events suggestive of vulvovaginitis, balanitis,
and related genital infection were more
frequently reported in all dapagliflozin groups
compared with placebo, and their frequency
increased with increasing dapagliflozin dose
(Table 2). The majority of these patients were
females, with most reporting the first event
during the short-term period (Fig. 3a). Events
suggestive of UTI were reported at similar rates
across all treatment groups (Table 2), and most
patients reported the first event during the
short-term period (Fig. 3b). No kidney
infections were reported. All of the events
suggestive of genital infections or UTIs were of
mild or moderate intensity, and only 1 patient
receiving dapagliflozin 10 mg discontinued the
study due to an AE suggestive of UTI. Cultures
were obtained only in a proportion of cases;
thus, not all reports represented confirmed
infections. Nevertheless, the majority of these
events were treated with antimicrobial agents.
For events suggestive of genital infection, 0 out
of a total of 2 events in the placebo group and
29 out of a total of 40 events across the
dapagliflozin groups were treated; repeated
treatment because of inadequate response was
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Table 2 Overall summary of patients with an AE over 48 weeks (safety analysis set)
Preferred term Placebo 1
glimepiride
(N5 146)
Dapagliﬂozin 2.5 mg 1
glimepiride (N5 154)
Dapagliﬂozin 5 mg 1
glimepiride (N5 145)
Dapagliﬂozin 10 mg 1
glimepiride (N5 151)
Overall summary of patients with an AE, n (%)
One or more AE 81 (55.5) 90 (58.4) 88 (60.7) 89 (58.9)
One or more drug-
related AEa
8 (5.5) 12 (7.8) 12 (8.3) 16 (10.6)
AE leading to
discontinuation
5 (3.4) 5 (3.2) 5 (3.4) 4 (2.6)
One or more SAEb 13 (8.9) 16 (10.4) 16 (11.0) 13 (8.6)
SAE leading to
discontinuation
3 (2.1) 3 (1.9) 1 (0.7) 1 (0.7)
Deaths 0 (0.0) 2 (1.3) 0 (0.0) 1 (0.7)
Patients with AEs of C3% in any group (by MedDRA preferred term), n (%)
Nasopharyngitis 10 (6.8) 6 (3.9) 11 (7.6) 10 (6.6)
Upper respiratory
tract infection
4 (2.7) 5 (3.2) 7 (4.8) 7 (4.6)
UTIc 7 (4.8) 5 (3.2) 4 (2.8) 6 (4.0)
Bronchitis 1 (0.7) 2 (1.3) 4 (2.8) 5 (3.3)
Arthralgia 5 (3.4) 8 (5.2) 0 (0.0) 3 (2.0)
Diarrhea 7 (4.8) 4 (2.6) 4 (2.8) 1 (0.7)
Dyspepsia 5 (3.4) 2 (1.3) 4 (2.8) 1 (0.7)
Cough 2 (1.4) 1 (0.6) 2 (1.4) 5 (3.3)
Dyslipidemia 0 (0.0) 5 (3.2) 2 (1.4) 4 (2.6)
Hypertension 10 (6.8) 9 (5.8) 5 (3.4) 3 (2.0)




10 (6.8) 15 (9.7) 15 (10.3) 17 (11.3)
Major episode 0 (0.0) 1 (0.6) 0 (0.0) 0 (0.0)
Minor episode 4 (2.7) 5 (3.2) 12 (8.3) 13 (8.6)
Other episode 7 (4.8) 11 (7.1) 5 (3.4) 5 (3.3)
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Table 2 continued
Preferred term Placebo 1
glimepiride
(N5 146)
Dapagliﬂozin 2.5 mg 1
glimepiride (N5 154)
Dapagliﬂozin 5 mg 1
glimepiride (N5 145)




Total 2 (1.4) 8 (5.2) 9 (6.2) 13 (8.6)
Males 0/71 (0.0) 1/77 (1.3) 2/72 (2.8) 5/66 (7.6)
Females 2/75 (2.7) 7/77 (9.1) 7/73 (9.6) 8/85 (9.4)
Events suggestive of
UTIf
Total 11 (7.5) 7 (4.5) 11 (7.6) 12 (7.9)
Males 1/71 (1.4) 1/77 (1.3) 4/72 (5.6) 4/66 (6.1)
Females 10/75 (13.3) 6/77 (7.8) 7/73 (9.6) 8/85 (9.4)g
Renal impairment/
failureh




0 (0.0) 1 (0.6) 0 (0.0) 1 (0.7)
N is the number of patients in the safety analysis set and includes data after rescue therapy
AE adverse event, MedDRA Medical Dictionary for Regulatory Activities, SAE serious adverse event, UTI Urinary tract
infection
a Events with certain, probable, possible, or unknown relation to study drug were deemed to be drug-related AEs
b No SAE was assessed as drug-related
c Based on deﬁnitive Medical Dictionary for Regulatory Activities preferred terms
d None led to study discontinuation
e Includes hypoglycemic events with onset on or after the ﬁrst date of double-blind treatment, and on or prior to the last
day of short-term or long-term double-blind treatment, plus 4 days or up to end of treatment visit if earlier. Major episode
deﬁned as a symptomatic episode requiring external (third party) assistance due to severe impairment in consciousness or
behavior with a capillary or plasma glucose value\3 mmol/L and prompt recovery after glucose or glucagon administration.
Minor episode deﬁned as either a symptomatic episode with a capillary or plasma glucose measurement \3.5 mmol/L,
regardless of need for external assistance, or an asymptomatic capillary or plasma glucose measurement\3.5 mmol/L that
did not qualify as a major episode. Other episodes of hypoglycemia deﬁned as suggestive episode reported but not meeting
the criteria for major or minor episodes
f Events suggestive of genital infection or UTI were identiﬁed in the database using the prespeciﬁed lists of preferred terms.
These events included signs, symptoms, and other reports suggestive of genital infection or UTI, as well as deﬁnitive terms
for genital infection or UTI
g One patient discontinued the study
h These events were also identiﬁed in the database using prespeciﬁed lists of preferred terms, which also included, for
example, laboratory values such as serum creatinine
i Two renal impairment and one renal failure
j Renal impairment
k Obstructive uropathy
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rarely required across the dapagliflozin groups
(4/40). For events suggestive of UTIs, 18 out of a
total of 19 events in the placebo group and 26
out of a total of 32 events across the
dapagliflozin groups were treated; repeated
treatment because of inadequate response was
rarely required (0/19 in the placebo group and
2/32 across the dapagliflozin groups).
AE reports of neoplasms (benign, malignant,
and unspecified) occurred in 1.3–3.9% of
patients in the dapagliflozin groups compared
with 1.4% of patients in the placebo group
(Supplementary Table S3 in the ESM).
Overall, changes in clinical laboratory
parameters from baseline to week 48 were
small in magnitude. There were small mean
increases in hematocrit (2.26–2.53%) in the
dapagliflozin groups that were not associated
with thromboembolic AEs. A small increase in
blood urea nitrogen (0.39–0.68 mmol/L) in the
dapagliflozin groups was not associated with
any worsening of renal function as evidenced
Fig. 3 Patients with events suggestive of a genital infections and b urinary tract infections (safety analysis set and include
data after rescue therapy). DAPA dapagliﬂozin, GLI glimepiride, PLA placebo
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by the lack of any meaningful changes in serum
creatinine, calculated creatinine clearance,
estimated glomerular filtration rate, and serum
cystatin-C (Supplementary Table S4 in the ESM).
DISCUSSION
The present study showed that the glycemic
efficacy of dapagliflozin appeared to be dose
dependent. The glycemic effect of dapagliflozin
versus placebo was evident at the first study
visit; a sustained, clinically meaningful effect
was demonstrated from 12 to 48 weeks in the
dapagliflozin 5-mg group and from 8 to
48 weeks in the 10-mg group. Moreover, the
placebo-corrected reductions in HbA1c
demonstrated with all dapagliflozin doses at
24 weeks [8] were maintained over 48 weeks. In
addition to these changes in HbA1c,
dapagliflozin treatment was associated with
sustained improvements in FPG over 48 weeks
and reductions in postprandial plasma glucose
rise in response to an OGTT at 24 weeks [8] and
48 weeks.
The proportion of patients requiring rescue
medication or discontinuing due to lack of
glycemic control was lower in the dapagliflozin
groups compared with placebo, with markedly
greater differences seen between the
dapagliflozin and placebo groups at the end of
the extension period than were noted at the end
of the short-term period [8]. A sharp increase in
the probability of rescue or discontinuation due
to lack of glycemic control was evident after
week 32 in all treatment groups (Fig. 2), which
can be explained by the change in criteria for
rescue therapy from an FPG [11.0 mmol/L
during the short-term treatment period to an
HbA1c C8.0% during the extension period.
Regarding additional clinical benefits with
dapagliflozin treatment, sustained reductions in
body weight and SBP were noted over 48 weeks,
consistent with findings observed in other
clinical studies of dapagliflozin [11–13]. Owing
to the insulin-dependent mechanism of action
of sulfonylureas, these agents are often
associated with weight gain [14]. The addition
of dapagliflozin to sulfonylurea therapy has the
potential, therefore, to not only improve
glycemic efficacy, but also to mitigate
sulfonylurea-associated weight gain.
Reductions in SBP have been shown to reduce
the incidence of cardiovascular events in
patients with hypertension [15, 16] and in
patients with T2DM [17, 18], the majority of
whom also have hypertension [19, 20]. Whether
the modest reductions in SBP observed with
dapagliflozin therapy translate into longer-term
reductions in cardiovascular risk await results
from the prospective DECLARE study
(Clinicaltrials.gov #NCT01730534) [21].
Overall, dapagliflozin was well tolerated.
Although hypoglycemic events were more
frequently reported in patients treated with
dapagliflozin than with placebo, most first
events occurred within the first 24 weeks of
treatment. An increase in such events is
commonly observed when glucose-lowering
therapies with a low intrinsic potential to
cause hypoglycemia are added to sulfonylurea
therapy [22].
A higher proportion of patients treated with
dapagliflozin (mostly female) reported events
suggestive of vulvovaginitis, balanitis, and
related genital infection compared with
placebo. Although patients with diabetes are at
increased risk of common infections, including
genital infections [23–27], an increase in rates of
events suggestive of genital infection has been
consistently reported in clinical studies of
dapagliflozin and canagliflozin [28–31]. Most
of these events occurred during the first
24 weeks, were of mild or moderate intensity,
responded to routine management, and rarely
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led to study discontinuation. Events suggestive
of UTI occurred in similar proportions of
patients in the dapagliflozin and placebo
groups, in line with similar findings of other
SGLT2 inhibitor therapies in patients with
T2DM [32]. Findings reported in the present
study were also similar to pooled analyses of 12
randomized, placebo-controlled trials of
dapagliflozin as monotherapy or add-on
therapy, which assessed the occurrence of
genital infections and UTIs over 24 weeks [33,
34]. These pooled analyses also demonstrated
that when actual clinical diagnoses of genital
infections and UTIs (as opposed to events
suggestive of) were considered, the proportions
of patients with an event decreased across
groups.
No deterioration of renal function was noted
in the dapagliflozin groups. Although
dapagliflozin was associated with modest rises
in hematocrit and blood urea nitrogen, there
were no changes in serum creatinine, creatinine
clearance, estimated glomerular filtration rate,
or serum cystatin-C (Supplementary Table S3).
Furthermore, there was no increase in the
proportions of patients experiencing AEs of
renal impairment/failure, or AEs of
hypotension/dehydration/hypovolemia
(Table 2).
The decrease from baseline in fasting
C-peptide to near normal levels observed with
dapagliflozin in this study is interesting, given
suggestions that high levels may be a marker for
hyperinsulinemia and insulin resistance [32].
Theoretically, as the mechanism of action of
dapagliflozin is independent of insulin
secretion, the reduction in fasting C-peptide
observed with treatment may be a result of
reduced stress on b-cells, which may ultimately
improve b-cell function over the long term.
Indeed, a recent, small-scale study of 11 patients
with T2DM demonstrated that lowering plasma
glucose concentration with dapagliflozin
improved insulin resistance and b-cell function
[35]. Further in-depth investigation, outside the
scope of the present study, is required to
comprehensively examine SGLT2-facilitated
relief of glucotoxicity in a clinical setting.
In our study, the proportion of patients with
neoplasms (benign, malignant, and
unspecified) was fractionally higher in the
dapagliflozin groups compared with placebo,
but no apparent anatomical pattern was noted.
An analysis of [4,500 patients included in the
dapagliflozin phase IIb/III database has
indicated that overall incidence rates for
malignant and unspecified tumors (per 100
patient-years) were similar for dapagliflozin
(1.34) versus control treatments (1.39) [36].
However, trends in specific malignancies will
continue to be evaluated in further
observational and randomized clinical studies.
Limitations of the study design have been
published previously [8]. Although excluding
data after rescue therapy allows changes
attributable to the investigational treatment to
be evaluated (Fig. 1a), the progressive loss of
patient numbers from the analysis limits the
confidence of these findings. Display of all
patient data, including after rescue therapy
(Supplementary Figure S2), shows that a high
number of patients completed the study.
Although including all treated patients comes
closer to actual clinical practice, interpretation
of the results is confounded by changes in
HbA1c and other variables consequent to the
addition of rescue medication. We have
reported both analyses to evaluate the
robustness of dapagliflozin treatment effects
and found that the adjusted mean changes
from baseline in HbA1c were similar between
the two analytic strategies.
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CONCLUSION
Loss of efficacy over time is observed with some
treatments for T2DM [2, 9]. To our knowledge,
this is the longest study to date of an SGLT2
inhibitor added to sulfonylurea monotherapy.
In this study, short-term efficacy observed at
24 weeks was maintained over the longer term.
Overall, treatment with dapagliflozin improved
glycemic control, body weight, and blood
pressure over a total of 48 weeks in patients
whose T2DM was inadequately controlled on
glimepiride. Although hypoglycemic events
and events suggestive of genital infections
were reported more often in patients receiving
dapagliflozin, therapy was well-tolerated in
general over 48 weeks. Given the common use
of sulfonylureas in the management of T2DM in
a number of countries, sustained efficacy and
long-term tolerability with add-on therapies of
complementary mechanisms of action such as
dapagliflozin are important to establish.
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